Hepatic profile analyses of tipranavir in Phase II and III clinical trials

BMC Infectious Diseases

Volumn 9, Issue , 2009, Pages

  Mikl, Jaromir ^a,b   Sulkowski, Mark S ^c   Benhamou, Yves ^d   Dieterich, Douglas ^e   Pol, Stanislas ^f   Rockstroh, Jürgen ^g   Robinson, Patrick A ^b   Ranga, Mithun ^b   Stern, Jerry O ^b  

^a UNIVERSITY AT ALBANY   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; PROTEINASE INHIBITOR; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TIPRANAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PYRIDINE DERIVATIVE; PYRONE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATTY LIVER; HEPATITIS B; HEPATITIS C; HEPATOSPLENOMEGALY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INCIDENCE; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; MIXED INFECTION; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SYMPTOMATOLOGY; TOXIC HEPATITIS; TREATMENT DURATION; ADOLESCENT; ADULT; AGED; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; KAPLAN MEIER METHOD; LIVER; MALE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; VIRUS HEPATITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; FEMALE; HEPATITIS, VIRAL, HUMAN; HIV INFECTIONS; HUMANS; KAPLAN-MEIERS ESTIMATE; LIVER; LIVER FAILURE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PYRIDINES; PYRONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; RITONAVIR; TRANSAMINASES; YOUNG ADULT;

EID: 74049112900     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-9-203     Document Type: Article

References (46)

1. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998, 9142:1725-1730.
2. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860. 10.1056/NEJM199803263381301, 9516219.
3. Vittinghoff E, Scheer S, O'Malley P, Colfax G, Holmberg SD, Buchbinder SP. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 1999, 179(3):717-720. 10.1086/314623, 9952385.
4. Drake JW. Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci USA 1993, 90:4171-4175. 10.1073/pnas.90.9.4171, 46468, 8387212.
5. Cooper D, Hall D, Jayaweera D, et al. Baseline phenotypic susceptibility to tipranavir/ritonavir is retained in isolates from patients with multiple protease inhibitor experience (BI 1182.52). [abstract 596]. Presented at: 10th Conference on Retroviruses and Opportunistic Infections; Boston 2003,
6. Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006, 368:466-475. 10.1016/S0140-6736(06)69154-X, 16890833.
7. Becker S. Liver Toxicity in Epidemiological Cohorts. Clinical Infectious Diseases 2004, 38:S49-S55. 10.1086/381447, 14986275.
8. Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol 2006, 44:S132-S139. 10.1016/j.jhep.2005.11.027, 16364487.
9. Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004, 18:2277-2284. 10.1097/00002030-200411190-00008, 15577540.
10. Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V. Hepatotoxicity after introduction of highly active antiretroviral therapy. [Letter]. AIDS 1998, 12:1256. 10.1097/00002030-199810000-00025, 9677182.
11. Luzuriaga K, McManus M, Mofenson L, Britto P, Graham B, Sullivan JL. A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med 2004, 350:2471-2480. 10.1056/NEJMoa032706, 15190139.
12. Crum NF, Riffenburgh RH, Wegner S, Agan BK, Tasker SA, Spooner KM, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006, 41:194-200. 10.1097/01.qai.0000179459.31562.16, 16394852.
13. Soriano V, Garcia-Samaniego J, Rodriguez-Rosado R, Gonzalez J, Pedreira J. Hepatitis C and HIV infection: biological, clinical, and therapeutic implications. J Hepatol 1999, 31(Suppl 1):119-123. 10.1016/S0168-8278(99)80387-0, 10622573.
14. Winnock M, Salmon-Ceron D, Dabis F, Chene G. Interaction between HIV-1 and HCV infections: towards a new entity?. J Antimicrob Chemother 2004, 53:936-946. 10.1093/jac/dkh200, 15117928.
15. Schiavini M, Angeli E, Mainini A, Zerbi P, Duca PG, Gubertini G, et al. Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985-2002. HIV Medicine 2006, 7:331-337. 10.1111/j.1468-1293.2006.00384.x, 16945079.
16. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000, 283:74-80. 10.1001/jama.283.1.74, 10632283.
17. Sauleda S, Martorell M, Esteban JI, Tural C, Ruiz I, Puig L, et al. Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade. Haemophilia 2006, 12:228-236. 10.1111/j.1365-2516.2006.01211.x, 16643206.
18. DAIDS National Institutes of Health, Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, version 1.0. 2004, DAIDS., http://www3.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/PDF/ DAIDSAEGradingTable.pdf
19. Sulkowski M, Rockstroh J, Soriana V, Stern J, Mikl J. Clinical course of increased LFTs and hepatic events associated with ritonavir (RTV)-boosted tipranavir (TPV/r) based therapy in the RESIST trials [abstract H-1899]. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco 2006,
20. Torti C, Lapadula G, Casari S, Puoti M, Nelson M, Quiros-Roldan E, et al. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. BMC Infectious Diseases 2005, 5:1-10. 10.1186/1471-2334-5-58, 547910, 15642116.
21. Bonfanti P, Landonio S, Ricci E, Martinelli C, Fortuna P, Faggion I, et al. Risk Factors for Hepatotoxicity in Patients Treated With Highly Active Antiretroviral Therapy. [Letter]. JAIDS Journal of Acquired Immune Deficiency Syndromes 2001, 27:316-318.
22. Becker S. Liver toxicity in epidemiological cohorts. Clin Infect Dis 2004, 38:S49-S55. 10.1086/381447, 14986275.
23. Gisolf EH, Dreezen C, Danner SA, Weel JL, Weverling GJ. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group. Clin Infect Dis 2000, 31:1234-1239. 10.1086/317449, 11073757.
24. Servin-Abad L, Molina E, Baracco G, Arosemena L, Regev A, Jeffers L, et al. Liver enzymes elevation after HAART in HIV-HCV co-infection. J Viral Hepat 2005, 12:429-434. 10.1111/j.1365-2893.2005.00617.x, 15985015.
25. Gathe JC, Pierone G, Piliero P, Arasteh K, Rubio R, Lalonde RG, et al. Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients. AIDS Res Hum Retroviruses 2007, 23:216-223. 10.1089/aid.2006.0178, 17263650.
26. Leith J, Walmsley S, Katlama C, et al. Pharmacokinetics and safety of tipranavir/ritonavir (TPV/r) alone or in combination with saquinavir (SQV), amprenavir (APV), or lopinavir (LPV): interim analysis of BI1182.51 [abstract 5.1]. Presented at: 5th International Workshop on Clinical Pharmacology of HIV Therapy; Rome 2004,
27. Cahn P, Villacian J, Lazzarin A, Katlama C, Grinsztejn B, Arasteh K, et al. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis 2006, 43:1347-1356. 10.1086/508352, 17051504.
28. Gathe J, Cooper DA, Farthing C, Jayaweera D, Norris D, Pierone G, et al. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin Infect Dis 2006, 43:1337-1346. 10.1086/508353, 17051503.
29. Pierone G, Drulak M, Arastéh K, et al. A long-term open-label rollover trial assessing the safety and tolerability of combination tipranavir and ritonavir (TPV/r) use in HIV-1-infected patients [poster WePe6.2C05]. Presented at: 3rd International AIDS Conference; Rio de Janeiro 2005,
30. Farthing C, Ward D, Hicks C, et al. Tipranavir/r demonstrates superior and durable treatment response compared with comparator PI/r in highly treatment experienced patients: Week 96 RESIST 1 and 2 results [abstract H-1385]. Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco 2006.
31. Hicks C, Cahn P, Jelaska A, Drulak M, Vinisko R. Tipranavir/r (TPV/r) maintains long term virological suppression - Week 156 results of RESIST [poster P7.3/25]. Presented at: 11th European AIDS Conference; Madrid 2007,
32. Orenstein R, Tsogas N. Looking Beyond Highly Active Antiretroviral Therapy: Drug-Related Hepatotoxicity in Patients with Human Immunodeficiency Virus Infection. Pharmacotherapy 2002, 22:1468-1478. 10.1592/phco.22.16.1468.33702, 12432973.
33. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002, 35:182-189. 10.1053/jhep.2002.30319, 11786975.
34. Sulkowski MS. Drug Induced Liver Injury Associated with Antiretroviral Therapy that Includes HIV 1 Protease Inhibitors. Clinical Infectious Diseases 2004, 38:S90-S97. 10.1086/381444, 14986280.
35. den Brinker M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van LR, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000, 14:2895-2902. 10.1097/00002030-200012220-00011, 11153671.
36. John R, Senior M, . AASLD-FDA-NIH-PhRMA Hepatotoxicity Steering Group Meeting 2006 Presentations Adaptation to Liver Injury Tacrine, Isoniazid, Ethanol, Experimental Drugs. 2006, AASLD-FDA-NIH-PhRMA Hepatotoxicity Steering Group Meeting 2006 Presentations., http://www.fda.gov/downloads/Drugs/ScienceResearch/ResearchAreas/ucm0793 27.pdf
37. Scherpbier HJ, Bekker V, van LF, Jurriaans S, Lange JM, Kuijpers TW. Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort. Pediatrics 2006, 117:e528-e536. 10.1542/peds.2005-1272, 16481448.
38. Kress KD. Antiretroviral-associated Hepatotoxicity. Curr Infect Dis Rep 2005, 7:103-107. 10.1007/s11908-005-0068-z, 15727736.
39. Brau N, Bini EJ, Shahidi A, Aytaman A, Xiao P, Stancic S, et al. Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York City metropolitan area. Am J Gastroenterol 2002, 97:2071-2078.
40. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002, 34:831-837. 10.1086/339042, 11833007.
41. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA 2002, 288:199-206. 10.1001/jama.288.2.199, 12095384.
42. Umeh OC, Currier JS. Sex differences in pharmacokinetics and toxicity of antiretroviral therapy. Expert Opin Drug Metab Toxicol 2006, 2:273-283. 10.1517/17425255.2.2.273, 16866613.
43. Guitton E, Montastruc JL, Lapeyre-Mestre M. Influence of HCV or HBV coinfection on adverse drug reactions to antiretroviral drugs in HIV patients. Eur J Clin Pharmacol 2006, 62:243-249. 10.1007/s00228-005-0080-0, 16416303.
44. Wester CW, Okezie OA, Thomas AM, Bussmann H, Moyo S, Muzenda T, et al. Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr 2007, 46:318-322. 10.1097/QAI.0b013e3181568e3f, 18090299.
45. Mould DR, Zhang X, Nieforth K, Salgo M, Buss N, Patel IH. Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients. Clin Pharmacol Ther 2005, 77:515-528. 10.1016/j.clpt.2005.02.005, 15961983.
46. Johnson MO, Charlebois E, Morin SF, Catz SL, Goldstein RB, Remien RH, et al. Perceived adverse effects of antiretroviral therapy. J Pain Symptom Manage 2005, 29:193-205. 10.1016/j.jpainsymman.2004.05.005, 15793937.